Disc Medicine (IRON) vs Recursion Pharmaceuticals (RXRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Disc Medicine (IRON) has outperformed Recursion Pharmaceuticals (RXRX) over the past year, losing 13.5% versus a loss of 35.1%. Over five years, IRON leads with a -45.5% price change compared with -79.3% for RXRX. Disc Medicine is the larger company by market cap ($2.39 billion vs $2.27 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRON | RXRX |
|---|---|---|
| Share price | $62.25 | $4.24 |
| Market cap | $2.39B | $2.27B |
| 1-day change | +2.43% | +7.34% |
| YTD return | -23.47% | -3.42% |
| 1-year return | -13.53% | -35.14% |
| 5-year return | -45.55% | -79.25% |
| EPS (TTM) | $-6.58 | $-1.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $74.68M |
| Revenue growth (YoY) | — | +26.92% |
| Net income (latest FY) | $-212.18M | $-644.76M |
| Gross margin | — | 4.99% |
| Operating margin | — | -867.87% |
| Net margin | — | -863.35% |
| 52-week high | $99.50 | $7.18 |
| 52-week low | $40.00 | $2.77 |
| Distance from 52-week high | -37.44% | -40.95% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +65.75% | +70.28% |
| Average volume | 471.18K | 20.70M |
| Shares outstanding | 38.39M | 535.34M |
| Employees | 165 | 600 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IRON has outperformed RXRX by 21.6 percentage points over the past year.
About Disc Medicine
IRON stock →Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 165 employees
About Recursion Pharmaceuticals
RXRX stock →Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 600 employees
IRON vs RXRX FAQ
Which is bigger, Disc Medicine or Recursion Pharmaceuticals?
Disc Medicine (IRON) is larger, with a market capitalization of $2.39B compared with $2.27B for Recursion Pharmaceuticals (RXRX).
Which stock has performed better over the past year, IRON or RXRX?
IRON returned -13.53% over the past 12 months, compared with -35.14% for RXRX (price return, excluding dividends). Past performance does not predict future results.
Are Disc Medicine and Recursion Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Disc Medicine and Biotechnology: Biological Products (No Diagnostic Substances) for Recursion Pharmaceuticals.